• Explore /
  • Poster
  • / Systemic and tumor-directed therapy for oligorecurrent metastatic prostate cancer (SATURN): Primary endpoint results of a phase II clinical trial.

Systemic and tumor-directed therapy for oligorecurrent metastatic prostate cancer (SATURN): Primary endpoint results of a phase II clinical trial.

Abstract Poster

Authors

null

John Nikitas

Department of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA

John Nikitas , Matthew Rettig , John Shen , Robert Evan Reiter , Alan Lee , Michael L. Steinberg , Luca Faustino Valle , Ankush Sachdeva , Tahmineh Romero , Jeremie Calais , Johannes Czernin , Nicholas George Nickols , Amar Upadhyaya Kishan

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Prostate Cancer

Track

Prostate Cancer - Advanced,Prostate Cancer - Localized

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT03902951

Citation

J Clin Oncol 42, 2024 (suppl 4; abstr 174)

DOI

10.1200/JCO.2024.42.4_suppl.174

Abstract #

174

Poster Bd #

H3

Abstract Disclosures

Similar Posters

First Author: Rana R. McKay

First Author: Nicholas George Nickols

First Author: Rana R. McKay

First Author: Diogo Assed Bastos